No

Date

Investors/

Licensee

Service Provider/

Licensor

Assets

Target·Modality

Indication

Stage

Deal

Value

(USD Mn)

1

9/3

Vignette

EpimAb Biotherapeutics

Monoclonal antibody

(EMB-06)

CD3

relapsed or refractory multiple myeloma and autoimmune disorders

Phase II

635

2

9/4

Eli Lilly

Haya Therapeutics

RNA-guided regulatory

genome platform

Multiple Novel lncRNA Targets

Metabolic Disorders

Preclinical

1,000

3

9/5

Eli Lilly

Genetic Intelligence

RNA-targeted artificial intelligence (AI)

technology platform

n/d

n/d

Discovery

409

4

9/12

Sanofi

Orano Med,

Radiomedix

Synthetic Peptide

Somatostatin Receptor Type 2

gastroenteropancreatic neuroendocrine tumors

Phase II

352.89

5

9/12

ITM Isotope Technologies

Debiopharm

Synthetic Peptide

(ITM-91)

Carbonic Anhydrase 9

Malignant

Mesothelioma,

Solid Tumor, Metastatic Colorectal Cancer,

 Metastatic Renal Cell

Carcinoma, Pancreatic Ductal Adenocarcinoma

Phase II

330.83

6

9/16

Novo Nordisk

Korro Bio

OPERA (Oligonucleotide Promoted

Editing of RNA) platform technology

RNA-Based Genome Editing

Cardiometabolic

diseases

Discovery

530

7

9/18

Novo Nordisk

NanoVation Therapeutics

onlong-circulating lipid nanoparticle

(lcLNP) technology

n/d

cardiometabolic

diseases and

unspecified rare

diseases

  Discovery

600

8

9/24

Novartis

Generate Biomedicines

AI platform “The Generate Platform”

n/d

n/d

Discovery

1,015

9

9/25

Sanofi

Tianjin Biopharma

Monoclonal antibody

(uliledlimab)

5' Nucleotidase

solid tumors

Phase III

237.29

10

9/30

BMS

Prime Medicine

Prime Assisted Site-Specific Integrase

 Gene Editing (PASSIGE™) technology

Ex vivo T-Cell Therapies

n/d

unspecified

Immunological

 disorders and cancer

Discovery

3,555.

No.

Date

Acquires

Issuer

주요 파이프라인

금액
(USD Mn)

1

9/3

Royalty Pharma

Ascendis Pharma A/S

palopegteriparatide

Type : Synthetic Peptide

Target : Parathyroid Hormone/Parathyroid Hormone Related

Peptide Receptor

Indication : Hypoparathyroidism

Stage : Marketed

150

2

9/18

Organon

Dermavant Sciences

tapinarof

Type : Small molecule

Target : Aryl Hydrocarbon Receptor

Indication : Atopic Dermatitis (Atopic Eczema),

Plaque Psoriasis (Psoriasis Vulgaris)

Stage : Marketed

1,200

3

9/23

Sanofi

Ventyx Biosciences

VTX-3232

Type : Small molecule

Target : NACHT LRR And PYD Domains Containing Protein 3

Indication : Multiple Sclerosis, Parkinson's Disease, Atherosclerosis, Obesity

Stage : Phase II

27

4

9/30

Genentech

Regor Pharmaceuticals

RGT-419B

Type : Small Molecule

Target : Cyclin Dependent Kinase 2

Indication : Metastatic Breast Cancer, Solid Tumor

Stage : Phase I

850